Mammogen, a company under the IV Bioholdings umbrella, received a Series A financing of up to $30 million. The funds will be used to advance their genTRU-breast test. The Series A positions Mammogen among the most significantly capitalized emerging companies in women’s health diagnostics at a moment when demand for more predictive, molecular approaches to screening is accelerating. Mammogen also announced the appointment of Elise Berman, M.D., as Chief Medical Officer. Dr. Berman brings more than two decades of leadership across breast imaging, medical affairs, and clinical development.
